Literature DB >> 24029222

Why proteasome inhibitors cannot ERADicate multiple myeloma.

Robert Z Orlowski1.   

Abstract

Proteasome inhibitors are key parts of our armamentarium against multiple myeloma, but the disease can become resistant through poorly defined mechanisms. In this issue of Cancer Cell, Leung-Hagesteijn and colleagues describe XBP1s(-) subpopulations of tumor cells that are resistant to bortezomib and may account for therapeutic failures in the clinic.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24029222      PMCID： PMC3863636          DOI： 10.1016/j.ccr.2013.08.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  Proteasome inhibitors in multiple myeloma: 10 years later.

Authors:  Philippe Moreau; Paul G Richardson; Michele Cavo; Robert Z Orlowski; Jesús F San Miguel; Antonio Palumbo; Jean-Luc Harousseau
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

2.  Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

Authors:  Chungyee Leung-Hagesteijn; Natalie Erdmann; Grace Cheung; Jonathan J Keats; A Keith Stewart; Donna E Reece; Kim Chan Chung; Rodger E Tiedemann
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

Review 3.  Latest advances and current challenges in the treatment of multiple myeloma.

Authors:  Anuj Mahindra; Jacob Laubach; Noopur Raje; Nikhil Munshi; Paul G Richardson; Kenneth Anderson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

4.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

5.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Authors:  John D Shaughnessy; Pingping Qu; Saad Usmani; Christoph J Heuck; Qing Zhang; Yiming Zhou; Erming Tian; Ichiro Hanamura; Frits van Rhee; Elias Anaissie; Joshua Epstein; Bijay Nair; Owen Stephens; Ryan Williams; Sarah Waheed; Yazan Alsayed; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

Review 6.  Epidemiology of multiple myeloma.

Authors:  Nikolaus Becker
Journal:  Recent Results Cancer Res       Date:  2011

7.  Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

Authors:  Jana Jakubikova; Sophia Adamia; Maria Kost-Alimova; Steffen Klippel; David Cervi; John F Daley; Dana Cholujova; Sun-Young Kong; Merav Leiba; Simona Blotta; Melissa Ooi; Jake Delmore; Jacob Laubach; Paul G Richardson; Jan Sedlak; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Blood       Date:  2011-02-14       Impact factor: 22.113

Review 8.  Personalizing oncology: perspectives and prospects.

Authors:  John Mendelsohn
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

9.  Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Authors:  Holly A F Stessman; Linda B Baughn; Aaron Sarver; Tian Xia; Raamesh Deshpande; Aatif Mansoor; Susan A Walsh; John J Sunderland; Nathan G Dolloff; Michael A Linden; Fenghuang Zhan; Siegfried Janz; Chad L Myers; Brian G Van Ness
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

10.  Future of cancer incidence in the United States: burdens upon an aging, changing nation.

Authors:  Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2009-04-29       Impact factor: 44.544
  10 in total
  21 in total

Review 1.  Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.

Authors:  Masaki Ri
Journal:  Int J Hematol       Date:  2016-05-12       Impact factor: 2.490

2.  The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma.

Authors:  Bingzong Li; Jinxiang Fu; Ping Chen; Xueping Ge; Yali Li; Isere Kuiatse; Hua Wang; Huihan Wang; Xingding Zhang; Robert Z Orlowski
Journal:  J Biol Chem       Date:  2015-10-19       Impact factor: 5.157

3.  Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Authors:  Christoph Driessen; Marianne Kraus; Markus Joerger; Hilde Rosing; Jürgen Bader; Felicitas Hitz; Catherine Berset; Alexandros Xyrafas; Hanne Hawle; Gregoire Berthod; Hermann S Overkleeft; Christiana Sessa; Alwin Huitema; Thomas Pabst; Roger von Moos; Dagmar Hess; Ulrich J M Mey
Journal:  Haematologica       Date:  2015-12-11       Impact factor: 9.941

4.  Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

Authors:  Xing-Ding Zhang; Veerabhadran Baladandayuthapani; Heather Lin; George Mulligan; Bin Li; Dixie-Lee W Esseltine; Lin Qi; Jianliang Xu; Walter Hunziker; Bart Barlogie; Saad Z Usmani; Qing Zhang; John Crowley; Antje Hoering; Jatin J Shah; Donna M Weber; Elisabet E Manasanch; Sheeba K Thomas; Bing-Zong Li; Hui-Han Wang; Jiexin Zhang; Isere Kuiatse; Jin-Le Tang; Hua Wang; Jin He; Jing Yang; Enrico Milan; Simone Cenci; Wen-Cai Ma; Zhi-Qiang Wang; Richard Eric Davis; Lin Yang; Robert Z Orlowski
Journal:  Cancer Cell       Date:  2016-04-28       Impact factor: 31.743

5.  Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.

Authors:  Subrahmanya D Vallabhapurapu; Sunil K Noothi; Derek A Pullum; Charles H Lawrie; Rachel Pallapati; Veena Potluri; Christian Kuntzen; Sohaib Khan; David R Plas; Robert Z Orlowski; Marta Chesi; W Michael Kuehl; P Leif Bergsagel; Michael Karin; Sivakumar Vallabhapurapu
Journal:  Nat Commun       Date:  2015-10-12       Impact factor: 14.919

6.  RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators.

Authors:  Alboukadel Kassambara; Laurie Herviou; Sara Ovejero; Michel Jourdan; Coraline Thibaut; Veronika Vikova; Philippe Pasero; Olivier Elemento; Jérôme Moreaux
Journal:  Leukemia       Date:  2021-04-06       Impact factor: 11.528

Review 7.  Clinical use of proteasome inhibitors in the treatment of multiple myeloma.

Authors:  Noah M Merin; Kevin R Kelly
Journal:  Pharmaceuticals (Basel)       Date:  2014-12-24

8.  In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Authors:  Ken Maes; Eva De Smedt; Alboukadel Kassambara; Dirk Hose; Anja Seckinger; Els Van Valckenborgh; Eline Menu; Bernard Klein; Karin Vanderkerken; Jérôme Moreaux; Elke De Bruyne
Journal:  Oncotarget       Date:  2015-02-20

9.  Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity.

Authors:  Ling Li; Hildur Knutsdottir; Ken Hui; Matthew J Weiss; Jin He; Benjamin Philosophe; Andrew M Cameron; Christopher L Wolfgang; Timothy M Pawlik; Gabriel Ghiaur; Andrew J Ewald; Esteban Mezey; Joel S Bader; Florin M Selaru
Journal:  JCI Insight       Date:  2019-01-24

10.  Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.

Authors:  Mohamed A Y Abdel Malek; Sajjeev Jagannathan; Ehsan Malek; Douaa M Sayed; Sahar A Elgammal; Hanan G Abd El-Azeem; Nabila M Thabet; James J Driscoll
Journal:  Oncotarget       Date:  2015-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.